Oric Pharmaceuticals, Inc.
ORIC Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to developing innovative cancer therapeutics designed to overcome resistance mechanisms that limit the efficacy of existing treatments. The company operates under the ticker symbol ORIC on the Nasdaq Global Select Market and maintains its… From the company’s description.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Oric Pharmaceuticals, Inc. does
In the company’s own words
ORIC Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to developing innovative cancer therapeutics designed to overcome resistance mechanisms that limit the efficacy of existing treatments. The company operates under the ticker symbol ORIC on the Nasdaq Global Select Market and maintains its corporate presence at oricpharma.com.
The company's pipeline centers on two lead clinical-stage product candidates. Rinzimetostat is an allosteric inhibitor of polycomb repressive complex 2 targeting the EED subunit, licensed from Mirati Therapeutics and currently in Phase 1b development for metastatic castration-resistant prostate cancer in combination with approved androgen receptor inhibitors. Enozertinib is a brain-penetrant, orally bioavailable irreversible inhibitor targeting EGFR exon 20 and EGFR atypical mutations, licensed from Voronoi Inc. and being evaluated in Phase 1b trials for non-small cell lung cancer with CNS metastases. The company has established clinical collaboration and supply agreements with Johnson & Johnson and Bayer to advance these programs.
ORIC's business model leverages the extensive oncology expertise of its founders and management team, who collectively have decades of experience identifying and developing cancer therapeutics including approved drugs such as Rozlytrek, Erleada, Gleevec, and Sprycel. The company applies a precision medicine approach utilizing biomarkers for target engagement demonstration and patient selection across its development programs.
The company's competitive advantages derive from its specialized expertise in three areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. ORIC maintains an integrated research and development infrastructure with in-house capabilities spanning biology, translational medicine, pharmacology, computational biology, biomarker development, clinical development, regulatory affairs, and commercial functions. As of December 31, 2025, the company employed 104 full-time employees.
In August 2025, ORIC announced a strategic pipeline prioritization to focus resources on advancing its two lead clinical programs, resulting in elimination of its discovery research group and substantial reduction in preclinical research activities. The company owns or licenses full worldwide development and commercialization rights to its programs, with the exception of enozertinib rights outside the ORIC Territory comprising mainland China, Hong Kong, Macau, and Taiwan.
Company details
- Sector
- Healthcare
- Industry
- Pharmaceutical Preparations
- Headquarters
- SOUTH SAN FRANCISCO, CA
- Fiscal year end
- December
- CIK
- 1796280
- SIC
- 2834
Financial performance, year by year
Fiscal 2020–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Oric Pharmaceuticals, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Oric Pharmaceuticals, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Oric Pharmaceuticals, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Oric Pharmaceuticals, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Oric Pharmaceuticals, Inc.'s last four quarterly filings that the numbers alone won't show?”